{"groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"FG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration =12.5 weeks)","id":"FG001","title":"Abiraterone Acetate or Enzalutamide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Poor compliance to protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"92"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"5"}],"type":"Investigator's decision"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"}],"type":"Participant's request"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"9"}],"type":"Other reason"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Randomized and not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"129"},{"groupId":"FG001","numSubjects":"126"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"126"},{"groupId":"FG001","numSubjects":"124"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"129"},{"groupId":"FG001","numSubjects":"126"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were randomized to receive either cabazitaxel or Androgen receptor (AR) targeted therapy (abiraterone or enzalutamide were assigned based on previous AR targeted treatment in which participants previously treated with abiraterone were treated with enzalutamide and vice versa due to resistance).","recruitmentDetails":"The study was conducted at 66 active centers in 13 countries. A total of 255 participants were randomized between 09 November 2015 to 13 November 2018, out of which 250 participants received treatment with the study drug."}